Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Developmental therapeutics

3994 - A First in Human Phase 1 Study of KPT-9274, a First in Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or NHL

Date

09 Sep 2017

Session

Developmental therapeutics

Presenters

Aung Naing

Citation

Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367

Authors

A. Naing1, S. Leong2, M.J. Pishvaian3, A.R.A. Razak4, A. Mahipal5, J. Berlin6, D. Cho7, W. Senapedis8, S. Shacham8, M. Kauffman8, J. Ellis8, J. Meade8, E. Baloglu8

Author affiliations

  • 1 Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Medical Oncology, University of Colorado Cancer Center Anschutz Cancer Pavilion, 80045 - Aurora/US
  • 3 Lombardi Comprehensive Cancer Center, Georgetown University, 200007 - Washington/US
  • 4 Department Of Medical Oncology And Hematology, Princess Margaret Cancer Centre, M5G2M9 - Toronto/CA
  • 5 Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 6 Medical Oncology, Vanderbilt Ingram Cancer Center, 37232-6307 - Nashville/US
  • 7 Medical Oncology, NYU Medical Oncology Associates, New York/US
  • 8 Clinical, Karyopharm Therapeutics, 02459 - Newton/US
More

Resources

Abstract 3994

Background

KPT-9274 is an oral, small molecule modulator of PAK4 (p21 activated kinase) and NAMPT (nicotinamide phosphoribosyltransferase). PAK4 is a major player in cell morphology and WNT/β-catenin signaling. NAMPT is the rate-limiting enzyme in NAD biosynthesis. Co-inhibition of these targets leads to synergistic anti-tumor effects through energy depletion, inhibition of DNA repair, cell cycle arrest, and ultimately apoptosis. Cells can utilize niacin to make NAD through an alternative pathway using NAPRT1. NAPRT1 is often absent in tumors making it a potential response biomarker. KPT-9274 demonstrates potent anti-tumor activity pre-clinically and in patient dogs with cancer.

Methods

This dose escalation study evaluates KPT-9274 as a single agent and co-dosed with niacin. KPT-9274 is given QoDx3/week (28-day cycle) at a starting dose of 10 mg. The objectives are to evaluate safety and tolerability of KPT-9274, dose-limiting toxicities (DLT), maximum tolerated dose (MTD), recommended phase 2 dose, early antitumor activities, pharmacokinetic (PK) and pharmacodynamic properties.

Results

As of 02-Mar-17, 14 patients (pts: 9M/5F; median age 61) with advanced solid tumors were enrolled in 4 cohorts (10 – 40 mg). One DLT (G4 anemia) at 40 mg was reported. MTD is not yet reached. Drug-related adverse events (AEs) include G2-4 anemia (6 pts, 43%) and G3 fatigue (1 pt, 7%). The most common G2 AEs are arthralgia and myalgia (3 pts; 21% each) and influenza-like illness (2 pts; 14%). Stable disease (SD) was seen in 29% of the 14 pts. Preliminary PK analysis suggests plasma exposure was dose proportional on C1D1 increasing 4 to 5-fold by C1D24. On C1D24, the mean Cmax and AUC0-t observed in 20 – 30 mg cohorts were 319 – 1,573 ng/mL and 10,456 – 59,152 ng*hr/mL, respectively. Preliminary data indicate that treatment of KPT-9274 reduces NAD levels vs. baseline in circulating leukocytes and tumor biopsies. Analyses to correlate NAPRT1 status with response is ongoing (2 of 4 SD pts are NAPRT1-).

Conclusions

Oral KPT-9274 is tolerated in pts with advanced solid malignancies. Anemia, arthralgias and myalgias are common AEs with one DLT (G4 anemia). PK is generally proportional and predictable.

Clinical trial identification

NCT02702492

Legal entity responsible for the study

Karyopharm Therapeutics Inc

Funding

Karyopharm Therapeutics Inc

Disclosure

W. Senapedis, S. Shacham, J. Meade, J. Ellis, E. Baloglu: Employee and a stock holder of Karyopharm Therapeutics. M. Kauffman: Employee, stock holder and member of board of directors at Karyopharm Therapeutics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.